1417694-01-9

Basic information

• Product Name: (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide trifluoroacetate
• Synonyms: (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide trifluoroacetate
• CAS NO: 1417694-01-9
• Molecular Weight: 666.719
• Mol File: 1417694-01-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide trifluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide trifluoroacetate(1417694-01-9)
• EPA Substance Registry System: (R)-N-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethyl]-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionamide trifluoroacetate(1417694-01-9)

Safety Data

• Hazardous Substances Data: 1417694-01-9(Hazardous Substances Data)

Upstream product

• 1417693-93-6 [(R)-1-[(S)-1-(4-cyano-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1417693-92-5 (S)-2-[(R)-2-tert-butoxycarbonylamino-3-(4-ethoxy-phenyl)-propionylamino]-3-phenyl-propionic acid 
• 87190-96-3 (S)-2-[(R)-2-tert-butoxycarbonylamino-3-(4-ethoxy-phenyl)-propionylamino]-3-phenyl-propionic acid methyl ester 
• 76757-92-1 (R)-2-((tert-butoxycarbonyl)amino)-3-(4-ethoxyphenyl)propanoic acid 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 1417693-99-2 [4-({(S)-2-[(R)-3-(4-ethoxy-phenyl)-2-methanesulfonylamino-propionylamino]-3-phenyl-propionylamino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 76-05-1 trifluoroacetic acid 

Relevant articles and documents

BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.